USPTO serial 88424911
DRIVEN BY SCIENCE INSPIRED BY HOPE
Reviewed by CopyMark Law Group
Status 605
- Filing date
- Status date
- Registration date
- —
- Examiner
- BUTLER, MIDGE
- Law office
- GENERIC WEB UPDATE
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with DRIVEN BY SCIENCE INSPIRED BY HOPE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Rockville, MD
Rockville, MD
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Devon E. White
Devon E. White WYRICK ROBBINS YATES & PONTON LLP4101 LAKE BOONE TRAIL, SUITE 300RALEIGH, NC 27607UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the prevention and treatment of disorders and diseases in or affecting the central nervous system; Pharmaceutical preparations for the treatment of the brain, central nervous system, and psychiatric and neurological diseases and disorders; Pharmaceutical preparations and substances for the prevention and treatment of major depressive disorder, mood disorder, psychosis, anxiety, epilepsy, sclerosis, porphyries, stroke, Huntington's disease, insomnia, Parkinson's disease, cognitive impairment; Pharmaceutical preparations for the treatment of ectoparasites, such as head lice; Steroids; Pharmaceutical preparations containing prednisolone for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculoskeletal system, the genitourinary system; Pharmaceutical preparations containing prednisolone for the treatment of inflammatory disorders; Pharmaceutical preparations containing prednisolone for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Medical delivery apparatus, namely, a valved holding chamber sold empty for use with metered dose inhalers; Cephalosporins; Antibiotics; Pharmaceutical preparations for the treatment of reflux, esophagitis, GERD (Gastro-Esophageal Reflux Disease), dyspepsia, heartburn, acid regurgitation, pyrosis, epigastric pain, irritative cough and dysphonia; Oral modified release, extended release, and/or sustained release pharmaceutical preparations for the drug carbinoxamine, a pharmaceutically acceptable salt thereof and/or carbinoxamine polistirex, intended for the treatment of seasonal and perennial allergic rhinitis, and other approved uses; Vitamin, mineral and fluoride preparations for human medical or nutritional uses; Nutritional preparation in the nature of nutritional supplement containing vitamins and fluoride; Pharmaceutical products and treatments for pediatric onset and rare and orphan disorders, namely, oral formulation of D-galactose for the treatment of phosphoglucomutase 1 (PGM1) deficiency (PGM1-CDG), oral formulation of D-mannose for the treatment of Mannose Phosphate Isomerase (MPI) deficiency (MPI-CDG), oral formulation of L-fucose for the treatment of Leukocyte Adhesion Deficiency Type II (LADII) (SLC35C1-CDG), nucleotide prodrug for the treatment of Deoxyguanosine Kinase (DGUOK) deficiency; Pharmaceutical products and treatments for pediatric onset and rare and orphan disorders, namely, oral formulations for the treatment of congenital disorders of glycosylation; Pharmaceutical products and treatments for pediatric onset and rare and orphan disorders, namely, oral nucleotide replacements for the treatment of Myelodysplastic Syndromes; Pharmaceutical preparations and substances for the treatment of neurogenic orthostatic hypotension (nOH) associated with neurodegenerative diseases such as Parkinson's Disease, Multiple Systems Atrophy, and Pure Autonomic Failure; Transmembrane AMPA receptor regulatory proteins (TARPs) for use as anticonvulsant agents and to modulate neurotransmission in patients with epilepsy; Oral neuro-selective adjunctive medications; Selective kappa opioid receptor (KOR) antagonist for the treatment of major depressive disorder (MDD) and for substance use disorders | ABANDONED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Dec 2, 2019 | MAB5 | ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION | — |
| Dec 2, 2019 | ABN5 | ABANDONMENT - AFTER PUBLICATION | — |
| Nov 26, 2019 | EXAR | TEAS EXPRESS ABANDONMENT RECEIVED | — |
| Oct 28, 2019 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Oct 8, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 8, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 18, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 5, 2019 | ALIE | ASSIGNED TO LIE | — |
| Sep 2, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 30, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 30, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 30, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 1, 2019 | GPRN | NOTIFICATION OF PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Aug 1, 2019 | GPRA | PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Aug 1, 2019 | CPRA | PRIORITY ACTION WRITTEN | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Jul 25, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| May 25, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 14, 2019 | NWAP | NEW APPLICATION ENTERED | — |